From R&D to GMP Exosomes Mass Production for Ongoing Clinical Phase I/II & Inflammation Related Indications
Time: 9:30 am
day: Day One
Details:
• Key elements to take into account during R&D and preclinical not lose years and funds in GMP transition process
• How to produce enough exosomes in a GMP-compliant way to answer clinical trial demand
• What does the regulatory pathway look like in Europe to start phase I/II
